Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Κυριακή 9 Απριλίου 2017

Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy

Up to now, platinum containing combination chemotherapy (cisplatin or carboplatin) administered with the anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR-AB) cetuximab is the only regimen able to prolong overall survival (OS) compared to chemotherapy alone in first-line r/mHNSCC [1]. In the trial, which lead to the approval of this combination, patients had a good performance status at inclusion (PS of 0–1) and median OS improved from 7.4 to 10.1 months (hazard ratio of cetuximab plus chemotherapy vs chemotherapy, 0.8; 95% CI, 0.64 to 0.99; P=0.04).

http://ift.tt/2oVYfWr

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου